MedTrace Logo

Case-Control Study of Inflammatory Breast Cancer in North Africa

NCT00793390 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 815

Last updated 2020-12-24

No results posted yet for this study

Summary

Background:

* Inflammatory breast cancer (IBC) is a rare, poorly understood and particularly aggressive form of breast cancer.
* Three characteristics of IBC tumors their rapid progression, their extensive formation of new blood vessels, and the fact that these characteristics are present from the inception of the tumor make it an ideal model for studying factors associated with tumor aggressiveness.
* This study is a collaboration among several institutions in the United States and North Africa that have extensive epidemiological experience and experience with IBC.

Objectives:

\- To understand what causes certain types of breast conditions, including IBC.

Eligibility:

\- Women 18 years of age and older with IBC and non-IBC and healthy women volunteers are eligible. Women who have had a previous diagnosis of any kind of breast cancer are excluded.

Design:

* Participants complete a questionnaire providing information about their background, including medical and reproductive history, family health history and lifestyle habits and undergo the following additional procedures:
* Height, weight, hip and chest measurements.
* Saliva sample collection to measure biological factors that may be related to breast conditions.
* Breast examination and, if permission is given, photographs of affected breast.
* Analysis of biopsied tissue for genetic and biochemical factors.

Conditions

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Gretchen Benson, Ph.D. · National Cancer Institute (NCI)

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-17
Primary Completion
2018-09-30
Completion
2018-09-30

Countries

  • Egypt
  • Morocco
  • Tunisia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00793390 on ClinicalTrials.gov